← 홈

Antibody · 흑색종

68개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 68개
AntibodystaleEli LillyPhase 1

Cetuximab Injection [Erbitux] (Cetuximab Injection [Erbitux])

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer; Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Mon… · EGFR

#EGFR#Antibody#Phase1#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 3

nivolumab (Opdivo, EU-authorized Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli LillyPhase 2

Encorafenib Oral Capsule + Cetuximab (Encorafenib Oral Capsule + Cetuximab)

Colorectal Cancer; BRAF V600E Mutation Positive · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAmgenPhase 3

nivolumab (Opdivo, FDA-licensed Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleZarour, Hassane, MDPhase 2

pembrolizumab (Keytruda, Fecal Microbiota Transplant with Pembrolizumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleGregory DanielsPhase 2

nivolumab (Opdivo, IL-2 and Nivolumab)

Melanoma Stage Iv; Renal Cell Carcinoma, Metastatic · Melanoma Stage Iv

#MelanomaStageIv#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleLinnaeus Therapeutics, Inc.Phase 3

ipilimumab and nivolumab (Immunotherapy, Immunotherapy (ipilimumab and nivolumab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Melanoma (Skin Cancer)

#MelanomaSkinCancer#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleLinnaeus Therapeutics, Inc.Phase 3

nivolumab and relatlimab (Immunotherapy, Immunotherapy (nivolumab and relatlimab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Melanoma (Skin Cancer)

#MelanomaSkinCancer#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Infliximab + Prednisone (Infliximab + Prednisone)

Renal Cell Carcinoma; Melanoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 6%임상시험 1상태 DISCONTINUED
AntibodystaleBristol Myers SquibbPhase 2

Ipilimumab IT (Ipilimumab IT)

Stage III/IV Melanoma · Stage III/IV Melanoma

#StageIIIIVMelanoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 21.4%임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

Ipilimumab Injection [Yervoy] (Ipilimumab Injection [Yervoy])

Malignant Melanoma · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

Ipilimumab and Fotemustine (Ipilimumab and Fotemustine)

Metastatic Malignant Melanoma · Metastatic Malignant Melanoma

#MetastaticMalignantMelanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab plus guadecitabine)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab)

Metastatic Cancer; Melanoma Cancer · Metastatic Cancer

#MetastaticCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

Ocular (Ipilimumab: Cohort 2, Ipilimumab: Cohort 2 (Ocular))

Metastatic Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleBrown UniversityPhase 2

Ipilumumab (Ipilumumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING

2 / 4 페이지

← 이전다음 →